Sorafenib



Indications and Reactions:

Role Indications Reactions
Primary
Hypertension 15.2%
Hepatic Neoplasm Malignant 11.0%
Drug Use For Unknown Indication 10.8%
Non-small Cell Lung Cancer 9.9%
Pain 7.7%
Metastatic Renal Cell Carcinoma 5.7%
Prophylaxis 5.4%
Renal Cell Carcinoma Stage Unspecified 4.8%
Nausea 3.5%
Diabetes Mellitus 3.5%
Constipation 3.3%
Renal Cell Carcinoma 3.2%
Diarrhoea 3.0%
Metastatic Malignant Melanoma 2.7%
Insomnia 2.1%
Abdominal Pain 2.0%
Prophylaxis Of Nausea And Vomiting 1.7%
Anaemia 1.6%
Depression 1.5%
Ascites 1.4%
Vomiting 15.5%
Pulmonary Embolism 9.6%
Thrombocytopenia 8.3%
Renal Failure 7.8%
Rash 6.1%
General Physical Health Deterioration 5.6%
Weight Decreased 4.9%
Pneumonia 4.7%
Pyrexia 4.4%
Sepsis 4.1%
Palmar-plantar Erythrodysaesthesia Syndrome 3.6%
Renal Failure Acute 3.3%
Respiratory Failure 3.3%
Hepatic Encephalopathy 3.2%
Pleural Effusion 3.1%
Syncope 2.9%
Deep Vein Thrombosis 2.6%
Diarrhoea 2.4%
Fatigue 2.3%
Dyspnoea 2.2%
Secondary
Product Used For Unknown Indication 12.7%
Hepatic Neoplasm Malignant 12.1%
Drug Use For Unknown Indication 12.0%
Hypertension 11.0%
Non-small Cell Lung Cancer 5.9%
Diarrhoea 5.1%
Pain 5.0%
Prophylaxis 4.3%
Nausea 4.3%
Diabetes Mellitus 3.8%
Ascites 3.3%
Insomnia 2.8%
Chronic Obstructive Pulmonary Disease 2.7%
Acute Myeloid Leukaemia 2.3%
Muscle Spasms 2.2%
Renal Cell Carcinoma 2.2%
Rash 2.2%
Renal Cell Carcinoma Stage Unspecified 2.1%
Enteritis 2.0%
Metastatic Renal Cell Carcinoma 2.0%
Vomiting 11.7%
Pulmonary Embolism 9.0%
Thrombocytopenia 8.6%
Oedema Peripheral 6.6%
Palmar-plantar Erythrodysaesthesia Syndrome 6.3%
Renal Failure 6.3%
Pyrexia 6.0%
Weight Decreased 5.3%
Deep Vein Thrombosis 4.8%
Tetany 4.4%
Off Label Use 4.0%
Anaemia 3.6%
Muscle Spasms 3.2%
Myocardial Infarction 3.1%
Toxicity To Various Agents 3.1%
Hypocalcaemia 2.9%
Pleural Effusion 2.9%
Dyspnoea 2.8%
Diarrhoea 2.7%
Hepatic Encephalopathy 2.7%
Concomitant
Product Used For Unknown Indication 21.1%
Metastatic Renal Cell Carcinoma 13.0%
Hepatic Neoplasm Malignant 8.3%
Acute Myeloid Leukaemia 7.2%
Pain 6.0%
Hypertension 5.6%
Renal Cell Carcinoma 5.4%
Metastases To Bone 5.0%
Renal Cancer 4.3%
Nausea 3.3%
Drug Use For Unknown Indication 2.9%
Vomiting 2.9%
Neoplasm Malignant 2.3%
Prophylaxis Against Graft Versus Host Disease 2.3%
Renal Cell Carcinoma Stage Unspecified 2.3%
Acral Lentiginous Melanoma Stage Unspecified 1.9%
Convulsion 1.7%
Cough 1.7%
Liver Transplant 1.7%
Renal Cancer Metastatic 1.4%
Wound Dehiscence 12.7%
Weight Decreased 7.8%
Osteonecrosis Of Jaw 6.9%
Anaemia 5.9%
Drug Ineffective 5.9%
Renal Cell Carcinoma 5.9%
Vomiting 5.9%
Death 4.9%
Troponin Increased 4.9%
Weight Increased 4.9%
White Blood Cell Count Decreased 4.9%
Cystoid Macular Oedema 3.9%
Pruritus 3.9%
Syncope 3.9%
Haemoglobin Abnormal 2.9%
Hepatic Neoplasm Malignant 2.9%
Infusion Related Reaction 2.9%
Large Intestine Perforation 2.9%
Palmar-plantar Erythrodysaesthesia Syndrome 2.9%
Pleural Effusion 2.9%
Interacting
Hepatic Neoplasm Malignant 28.0%
Anticoagulant Therapy 16.0%
Acute Myocardial Infarction 14.0%
Drug Use For Unknown Indication 10.0%
Hiv Infection 10.0%
Hypertension 6.0%
Atrial Fibrillation 4.0%
Hepatocellular Carcinoma 4.0%
Metastatic Malignant Melanoma 4.0%
Acute Myeloid Leukaemia 2.0%
Prophylaxis 2.0%
International Normalised Ratio Increased 25.0%
Drug Interaction 16.7%
Gastrointestinal Angiodysplasia 12.5%
Asthenia 8.3%
Myalgia 8.3%
Stomatitis 8.3%
Abdominal Pain 4.2%
Chemotherapeutic Drug Level Increased 4.2%
Gastrointestinal Haemorrhage 4.2%
Squamous Cell Carcinoma 4.2%
Treatment Noncompliance 4.2%